(TheNewswire)
LONDON, ONTARIO – TheNewswire - February 4, 2021 – Sernova Corp. (TSXV:SVA)(OTCQB:SEOVF) (FSE:PSH), a leading clinical-stage regenerativemedicine therapeutics company, is pleased to announce the start oftrading of Sernova shares on Xetra, the electronic trading system ofDeutsche Börse AG in Germany (German Securities Identification Number(WKN): A0LBCR , International Securities Identification Number (ISIN): CA81732W1041 , German Ticker-Symbol: PSH).
Xetra is an electronic trading platform operated by the FrankfurtStock Exchange. It offers trading in stocks, funds, bonds, warrants,and commodities contracts. Launched in 1997, the majority of stockmarket transactions in Germany are through the Xetra trading venue:approximately 90 percent of all trading in shares across all Germanexchanges is now conducted through Xetra making it the largest ofGermany’s stock exchanges. Over 200 trading participants from 16European countries, United Arab Emirates and Hong Kong are connectedvia Xetra servers.
Xetra is the first and primary choice for institutionalinvestors with its significantly higher liquidity and narrower price spreads. Given the high turnover (liquidity) on the Xetratrading venue, orders for securities are executed swiftly and atprices in line with the market. Moreover, this principle is supportedby Designated Sponsors who post binding purchaseand selling prices (quotes) continuously and thus ensure additionalliquidity and fair prices, making it the first choice forinstitutional investors. mwb Wertpapierhandelsbank AG will act asDesignated Sponsor (active market maker) to handle the trading ofSernova’s shares on Xetra with immediate effect and thereforecontribute to increased trading liquidity.
mwb fairtrade Wertpapierhandelsbank AG ( www.mwbfairtrade.com ) is a securities service provider licensed by the GermanFederal Financial Supervisory Authority (BaFin) with branches nearMunich, Hamburg, Hanover, Frankfurt as well as Berlin. Founded in1993 and active in two business divisions: Securities Trading andCorporates & Markets, mwb manages approximately 40,000 order booksfor German and international securities as well as 89 DesignatedSponsors mandates making mwb one of the largest order book managers inGermany.
“ mwb has developed in-depthknowledge on enabling Xetra trading for overseas companies. We are happy to support Sernova with the rollout of their exciting equity storyand look forward to enhance Euro-based trading possibilities for their institutionaland retail investor base in Europe,” said Sascha Guenon, Head ofDesignated Sponsoring and Corporate Broking at mwb.
“We are experiencing a significant increase ofinterest from institutional investors in Europe, especially inGerman-speaking countries, and want to provide them with a moreefficient way to trade ourshares," commented Dr. Philip Toleikis, President and CEO ofSernova. "This is an important step to increase the percentage oflong-term oriented institutional investors within our group ofshareholders who understand the potential of our innovative platformtechnologies in the regenerative medicine field as well as the valuation gapwith our competitors . mwb has a strong network ofbiotech investors and we are looking forward to presenting thepotential of Sernova’s regenerative medicine platform to them .”
ABOUT SERNOVA
Sernova is developing regenerative medicine therapeutic technologiesusing a medical device and immune protected therapeutic cells (i.e.human donor cells, corrected human cells and stem cell-derived cells)to improve the treatment and quality of life of people with chronicmetabolic diseases such as insulin-dependent diabetes, blood disordersincluding hemophilia, and other diseases treated through replacementof proteins or hormones missing or in short supply within the body.For more information, please visit www.sernova.com
For further information contact:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
FORWARD-LOOKING INFORMATION
This release may contain forward-looking statements. Forward-lookingstatements are statements that are not historical facts and aregenerally, but not always, identified by the words “expects”,“plans”, “anticipates”, “believes”, “intends”,“estimates”, “projects”, “potential” and similarexpressions, or that events or conditions “will”, “would”,“may”, “could” or “should” occur. Although Sernovabelieves the expectations expressed in such forward-looking statementsare based on reasonable assumptions, such statements are notguarantees of future performance, and actual results may differmaterially from those in forward-looking statements. Forward-lookingstatements are based on the beliefs, estimates, and opinions ofSernova’s management on the date such statements were made, whichinclude our beliefs about the conduct and outcome of clinical trials.Sernova expressly disclaims any intention or obligation to update orrevise any forward-looking statements whether as a result of newinformation, future events or otherwise.
Copyright (c) 2021 TheNewswire - All rights reserved.